RxDoctor Payments DataLook up a doctor →

Leon Barkodar, MD

Neurology · West Hills, CANPI 1760700496

Payments from drug & device makers

$1,994,448in general payments, 2019–2025

Across 339 payments — averaging $5883.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$1.3M
  • Eli Lilly$563K
  • E.r. Squibb & Sons, L.L.C.$73K
  • Bristol Myers Squibb$29K
  • AbbVie$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • plus $2K from 18 others
$13,268in research payments, 2019–2025

Across 5 payments — averaging $2653.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$13K

What the payments were for

  • Speaking & faculty fees$15,67580%
  • Food & beverage$3,81419%
  • Education$1971%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,994,448 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$218,373
Medicare patients
412
Services billed
4,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina65$75,417
Nurtec OdtRimegepant Sulfate45$57,841
UbrelvyUbrogepant17$20,950
QuliptaAtogepant17$19,928
EliquisApixaban19$18,481
Ajovy SyringeFremanezumab-Vfrm14$17,243
Lamotrigine ErLamotrigine24$12,123
Dalfampridine ErDalfampridine14$10,334
Entacapone72$9,769
Emgality PenGalcanezumab-Gnlm14$9,541
Carbidopa-LevodopaCarbidopa/Levodopa286$9,364
Memantine Hcl144$5,535
Rasagiline Mesylate27$5,385
Divalproex Sodium ErDivalproex Sodium43$5,103
Rivastigmine18$4,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$12,036$116,29599 claims
PfizerNurtec Odt, Eliquis, Dilantin$311$77,81175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →